Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...

Discover why Bristol-Myers Squibb's undervalued stock, strong cash flow, and 5% dividend yield make it an attractive buy ...

The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader market significantly in Q2 2025. With a 12.12% weighting in the S&P 500, ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) has received an average rating of “Hold” from the twenty-two brokerages that are presently covering the firm, MarketBeat reports. Two ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $47.51, moving +2.64% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.11%. On the ...

This Big Pharma company is positioned for a rebound while continuing to pay investors a sizable dividend yield.

Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect ...

The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a ...

See the latest Bristol-Myers Squibb Co stock price (BMY:XNYS), related news, valuation, dividends and more to help you make your investing decisions.